1. Membrane Transporter/Ion Channel
    Neuronal Signaling
  2. iGluR

Talampanel (Synonyms: GYKI-53773; LY-300164)

Cat. No.: HY-15079 Purity: 98.50%
Data Sheet SDS Handling Instructions

Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED).

For research use only. We do not sell to patients.
Talampanel Chemical Structure

Talampanel Chemical Structure

CAS No. : 161832-65-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $88 In-stock
5 mg $80 In-stock
10 mg $120 In-stock
50 mg $410 In-stock
100 mg $660 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED). Target: AMPA [1] in vitro: Talampanel is a glutamate receptor inhibitor with anti-seizure activity. in vivo: Talampanel reduces motoneuronal calcium in a mouse model of ALS, but its effi cacy declines as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00982150 Teva Pharmaceutical Industries Amyotrophic Lateral Sclerosis September 2009 Phase 2
NCT00964730 Teva Pharmaceutical Industries|Cetero Research, San Antonio Healthy October 2009 Phase 1
NCT00868361 Teva Pharmaceutical Industries|Covance Healthy May 2009 Phase 1
NCT00696332 Teva Pharmaceutical Industries ALS September 2008 Phase 2
NCT00267592 Teva Pharmaceutical Industries Glioblastoma Multiforme December 2005 Phase 2
NCT00036296 Teva Pharmaceutical Industries Dyskinesias|Parkinson Disease|Movement Disorders December 2006 Phase 1|Phase 2
NCT00064363 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Brain and Central Nervous System Tumors June 2003 Phase 2
NCT00062504 Teva Pharmaceutical Industries|National Cancer Institute (NCI) Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Oligoastrocytoma July 2003 Phase 2
NCT00057460 National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Healthy April 2003 Phase 2
NCT00108667 National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Parkinson Disease April 2005 Phase 2
NCT00034814 Teva Pharmaceutical Industries Epilepsy January 2002 Phase 2
View MoreCollapse
References
Molecular Weight

337.37

Formula

C₁₉H₁₉N₃O₃

CAS No.

161832-65-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Talampanel
Cat. No.:
HY-15079
Quantity: